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In this issue of the Journal, Tamaki et al. (1) describe the 
development of the ability to monitor left ventricular ejec-
tion fraction on a continuous basis while ambulatory patients 
perform various daily activities. A modified V5 electrocar-
diographic (ECG) lead was also continuously recorded dur-
ing the same activities. A transient decrease in left ventric-
ular ejection fraction lasting :::: 1 min was found on 36 
occasions in 16 patients with significant coronary heart 
disease, but only 12 of the episodes were accompanied by 
chest pain or dyspnea. ECG ST segment depression sugges-
tive of myocardial ischemia was found during 6 of the 12 
symptomatic and 5 of the 24 asymptomatic episodes. In 10 of 
the 12 symptomatic episodes, left ventricular ejection frac-
tion decreased 30 to 90 s before symptoms developed. These 
observations suggest that continuous monitoring of both left 
ventricular ejection fraction and the ECG for a period of 
several hours may allow a more sensitive identification of 
myocardial ischemia during normal daily activities than is 
possible with currently available methods. 
The "VEST". The ambulatory ventricular function mon-
itor ("VEST") is an extension of a probe device concept 
described by Wagner et al. (2) in 1976 for the repetitive 
measurement of left ventricular function at the bedside. 
They called the probe device a "nuclear stethoscope," and 
they and other authors (3-5) demonstrated that the nuclear 
stethoscope measurements of left ventricular ejection frac-
tion correlated well with gamma camera or contrast ventric-
ulographic measurements of ejection fraction in the same 
patients. The VEST device extends this concept and permits 
continuous measurement of left ventricular function during 
everyday activities (1,6,7). VEST measurements of left 
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ventricular ejection fraction calculated from the 15 to 30 s 
average time-activity curves have been shown to correlate 
well with gamma camera measurements of left ventricular 
ejection fraction in normal subjects and in patients with 
coronary heart disease (1,6-8). Thus, it appears that Tamaki 
and Strauss and their colleagues have developed a noninva-
sive technique for the ambulatory measurement of left 
ventricular ejection fraction in patients. 
Clinical application. The VEST should be an asset in the 
evaluation of 1) patients with chest pain of uncertain etiol-
ogy; 2) patients complaining of dyspnea with effort when it is 
not clear whether the dyspnea might be caused by pulmo-
nary or cardiac disease; 3) "silent" myocardial ischemia; 4) 
defining appropriate exercise limits for patients with under-
lying cardiovascular disease; and 5) providing prognostic 
insight in the identification of patients with coronary heart 
disease at risk for future coronary disease events, including 
death, myocardial infarction, the development of unstable 
angina and the need for coronary artery revascularization (9-
12). It has been demonstrated previously (9,10) that patients 
with coronary heart disease and unstable angina with con-
tinuing ST-T wave changes atrest and during low levels of 
activity are at risk for future coronary events, including new 
myocardial infarction, death and the need for some form of 
coronary artery revascularization. Furthermore, Corbett et 
al. (11,12) have demonstrated that low level exercise testing 
with monitoring of ventricular function and the identification 
of patients with decreases in left ventricular ejection fraction 
or increases in left ventricular end-systolic volume, or both, 
identifies a subset of patients after myocardial infarction at 
risk for future important coronary events. The ability to 
measure ambulatory alterations in left ventricular ejection 
fraction in patients with coronary heart disease should allow 
one to test the efficacy of selected medical regimens and 
identify patients who remain at risk for future coronary 
events despite an adequate medical regimen. 
Future developments. One may anticipate that there will 
be further methodologic developments with the VEST sys-
tem. Ideally, the VEST system will ultimately have the 
ability to measure segmental ventricular function objectively 
and quantitatively. Coronary heart disease initially results in 
alterations in segmental ventricular function, and it seems 
likely that some ischemic responses to stress and exercise 
will be missed if only global left ventricular function is 
analyzed. Thus, the information provided by the VEST 
would be more sensitive, and possibly more specific, for 
coronary heart disease if segmental function is also ana-
lyzed. It will be necessary to develop methods that allow one 
to be more certain about the orientation of the VEST 
detector in regard to the optimal orientation of the detector 
and the left ventricular blood pool so that even slight 
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alterations in position of the VEST detector with respect to 
the left ventricle may be identified and prevented. It will be 
necessary to develop VEST systems that will be applicable 
to patients of different body sizes and configurations. Fi-
nally, additional studies need to be done to demonstrate that 
the information provided by the VEST actually helps in 
optimal decision making regarding therapy for patients and 
by providing prognostic insight so that at least subsets of 
patients at risk for future important coronary events are 
identified before their occurrence. 
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